Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for...

Area of Science:

• Neuroscience
• Immunology
• Alzheimer Disease Research

Background:

• Activated microglia are present in Alzheimer disease (AD) brains, suggesting inflammation's role in AD pathogenesis.
• Transgenic mouse models overexpressing amyloid precursor protein (APP) exhibit amyloid plaques and microglial activation similar to human AD.
• Microglial activation and inflammatory markers increase with age in these AD mouse models.

Purpose of the Study:

• To investigate the complex nature of microglial activation in Alzheimer disease pathogenesis.
• To determine if enhanced microglial activation can modulate Alzheimer disease pathology.
• To explore distinct macrophage activation states and their potential relevance to brain monocyte-derived cells.

Main Methods:

• Utilized transgenic mouse models overexpressing the amyloid precursor protein (APP) gene.
• Administered anti-amyloid-beta (Abeta) immunotherapy to amyloid-depositing mice.
• Monitored age-dependent changes in microglial activation and inflammatory markers.
• Surveyed peripheral macrophage literature to identify distinct activation states and markers.

Main Results:

• Further activation of microglia/macrophages in APP transgenic mice led to reduced pathology in several instances.
• Anti-Abeta immunotherapy induced complex changes in microglial markers, challenging the assumption of monotonic activation.
• Peripheral macrophage research indicates at least two distinct activation states with differing tissue consequences.

Conclusions:

• Microglial activation in Alzheimer disease is not a uniform process and cannot be solely represented by a single marker.
• Targeting inflammatory responses in AD requires a nuanced understanding of different microglial/macrophage activation states.
• Markers identified in peripheral macrophage studies may be valuable for characterizing monocyte-derived cells in the brain.